- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05306431
Comparison of Antimicrobial Action of Sodium Hypochlorite and Polyhexamethylene Biguanide as Root Canal Irrigants
February 20, 2023 updated by: Hira Abbasi, Altamash Institute of Dental Medicine
Comparison of Antimicrobial Action of Sodium Hypochlorite and Polyhexamethylene Biguanide as Root Canal Irrigants in Patients Reporting With Non-vital Necrotic Pulp and Apical Periodontitis
The aim of this randomized clinical trial is to compare the antibacterial effects of sodium hypochlorite (NaOCl) and Polyhexamethylene biguanide during root canal treatment .
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study will compare the antibacterial effectiveness of sodium hypochlorite and PHMB, to find out whether PHMB can be used as a substitute to NaOCL.
Polyhexamethylene biguanide (PHMB), is a disinfectant solution having a broad spectrum of antimicrobial activity and is investigated as an endodontic irrigant.
It is non-corrosive, non-toxic and acts by disrupting cell membrane integrity.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Sindh
-
Karachi, Sindh, Pakistan, 75500
- Hira Danish
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
• Patients aged 18 to 50 years
- Both male and female patients
- Periodontally healthy teeth as determined by Periodontal Probing
- Patients with non-vital necrotic pulps as determined by Cold Test
- Patients with acute apical periodontitis determined by history and clinical examination
- Clinical Findings:
Visual: Carious tooth decay Occlusion: Hyperocclusion Pulp vitality test: Negative Periapical radiograph: Caries involving pulp space and PDL widening Percussion Test: Positive Palpation Test: Negative
• Single rooted teeth as determined radiographically
Exclusion Criteria:
• Multirooted teeth
- Teeth undergoing Re-endo treatments
- Teeth with root fractures and/ non restorable determined by clinical and radiographic examination
- Patients receiving antibiotic treatment in the past 3 months determined by history
- Patient with Diabetes determined by history
- Patient with history of smoking
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Polyhexamethylene biguanide
Polyhexamethylene biguanide (PHMB), is a disinfectant solution having a broad spectrum of antimicrobial activity and is investigated as an endodontic irrigant.
It is non-corrosive, non-toxic and acts by disrupting cell membrane integrity.
PHMB 0.2% has been recently used as a root canal irrigant in vitro and has shown promising results of antimicrobial effectiveness of > 99.9% for both PHMB and Sodium hypochlorite
|
Polyhexamethylene biguanide (PHMB), is a disinfectant solution having a broad spectrum of antimicrobial activity and is investigated as an endodontic irrigant
Other Names:
|
|
Experimental: Sodium Hypochloride
A number of irrigant solution has thus been proposed to serve the purpose, the most popular being sodium hypochlorite (NaOCl) because of its excellent antimicrobial activity but also the ability to dissolve organic matter.
|
A number of irrigant solution has thus been proposed to serve the purpose, the most popular being sodium hypochlorite (NaOCl) because of its excellent antimicrobial activity but also the ability to dissolve organic matter
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bacterial load assessed by culture
Time Frame: 24 hours
|
Effectiveness of irrigant will be evaluated with the existence or non-existence of bacteria: Positive Effect = no bacteria exist, Negative Effect = bacteria exist.
Bacterial analysis will be performed by counting the number of colonies of bacteria in the specimen: No growth = no colonies seen, Few growths = less than 10 colonies of bacteria seen, Moderate growth = less than 100 colonies more than 10 colonies of bacteria seen, Heavy growth = more than 100 colonies of bacteria seen.
|
24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2022
Primary Completion (Actual)
June 1, 2022
Study Completion (Actual)
November 30, 2022
Study Registration Dates
First Submitted
March 19, 2022
First Submitted That Met QC Criteria
March 29, 2022
First Posted (Actual)
April 1, 2022
Study Record Updates
Last Update Posted (Estimate)
February 21, 2023
Last Update Submitted That Met QC Criteria
February 20, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Root canal Irrigiant
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Irreversible Pulpitis
-
Tehran University of Medical SciencesActive, not recruitingSymptomatic Irreversible Pulpitis (SIP) | Symptomatic Irreversible Pulpitis With Apical PeridontitisIran
-
Cairo UniversityNot yet recruitingPulpitis - Reversible | Pulpitis - Irreversible
-
Mansoura UniversityCompletedIrreversible Pulpitis | Reversible PulpitisEgypt
-
Urooj FatimaNot yet recruitingSymptomatic Irreversible Pulpitis | Irreversible Pulpitis | Asymptomatic Irreversible PulpitisPakistan
-
Cukurova UniversityCompletedPulpitis - IrreversibleTurkey (Türkiye)
-
Jamia Millia IslamiaRecruiting
-
Cairo UniversityNot yet recruiting
-
Minia UniversityNot yet recruiting
-
Chulalongkorn UniversityNot yet recruiting
-
Sirawut Hiran-usChulalongkorn UniversityActive, not recruiting
Clinical Trials on Polyhexamethylene biguanide
-
SIFI SpACompleted
-
Universidade do Vale do SapucaiCompletedPeriodontal Diseases | Dental Plaque | Caries | Periimplantitis | Oral Surgical Wound Infection
-
AGUNCO Obstetrics and Gynecology CentreCompletedAntisepsis Regimen After Surgical Treatment of HPV Infected LesionsItaly
-
Jeremy Keenan, MD, MPHJohns Hopkins University; Baylor College of Medicine; University of Pennsylvania and other collaboratorsRecruitingAcanthamoeba KeratitisUnited States, Brazil, United Kingdom, India
-
Shiga UniversityOsaka University; Kanazawa Medical University; Nagahama Red Cross Hospital; Nagahama... and other collaboratorsUnknownType 2 Diabetes MellitusJapan
-
Medical University of ViennaCompleted
-
SanofiCompletedType 2 Diabetes MellitusJapan
-
Eli Lilly and CompanyCompletedType 2 Diabetes MellitusJapan
-
Katherine D. CrewCompletedBreast Neoplasms | Stage 0 Breast Carcinoma | Stage I Breast Carcinoma | Stage II Breast Carcinoma | Stage III Breast CarcinomaUnited States
-
SanofiCompletedOsteoporosis, Postmenopausal